Barclays
SION

Barclays’s Sionna Therapeutics SION Stock Holding History

Barclays’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286K Sell
6,495
-11,890
-65% -$476K ﹤0.01% 3515
2026
Q1 		$737K Sell
18,385
-29,787
-62% -$1.14M ﹤0.01% 2942
2025
Q4 		$1.98M Buy
48,172
+30,529
+173% +$1.16M ﹤0.01% 2936
2025
Q3 		$519K Sell
17,643
-5,379
-23% -$117K ﹤0.01% 3792
2025
Q2 		$399K Buy
+23,022
New +$302K ﹤0.01% 3890

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Barclays's SION Position: Q2 2026 in Review

Barclays reduced its Sionna Therapeutics (SION) stake by 65% in Q2 2026, selling an estimated $476K and leaving 6,495 shares worth $286K. The position accounts for ﹤0.01% of the portfolio, ranked #3515.

Barclays first reported a position in SION in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.98M in Q4 2025. 146 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Barclays held 6,495 shares of Sionna Therapeutics worth $286K as of Q2 2026.
  • Barclays sold 11,890 Sionna Therapeutics shares in Q2 2026, an estimated $476K.
  • Sionna Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3515 holding.
  • Barclays first reported a position in Sionna Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Barclays's Sionna Therapeutics position peaked at $1.98M in Q4 2025.
  • 146 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.